SRDX (Surmodics) Total Current Assets : $71.8 Mil (As of Dec. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Surmodics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Surmodics's total current assets for the quarter that ended in Dec. 2024 was $71.8 Mil.

Surmodics Total Current Assets Historical Data

The historical data trend for Surmodics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Total Current Assets Chart

Surmodics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Total Current Assets

Get a 7-Day Free Trial

86.61

70.26

57.59

86.69

81.30

Surmodics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Current Assets	Get a 7-Day Free Trial															79.81	84.26	80.36	81.30	71.85

Surmodics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Surmodics's Total Current Assets for the fiscal year that ended in Sep. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	40.112	+	23.272	+	15.168	+	2.752
	=	81.3

Surmodics's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	30.145	+	22.538	+	15.261	+	3.905
	=	71.8

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Surmodics (NAS:SRDX) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Surmodics's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	30.145	-	51.971	+	0.75 * 12.559	+	0.5 * 15.261
=	-4.8

Surmodics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Surmodics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Surmodics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (NAS:SRDX) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

9924 West 74th Street, Eden Prairie, MN, USA, 55344

Website

https://www.surmodics.com

Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.

Executives

Timothy J. Arens	officer: General Manager - IVD	9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344
Jose H Bedoya	director
David Dantzker	other: See Explanation of Responses	80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021
Kalich Ronald B Sr	director
Gary R Maharaj	director, officer: President & CEO	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Joseph J. Stich	officer: VP, Corp Dev & Strat Planning	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Charles W Olson	officer: General Manager
John D. Manders	officer: Corporate Controller	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gordon S. Weber	officer: Sr. VP of Legal, GC and Sec.	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Nusrath Sultana	officer: VP, Clinical Affairs	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Lisa Wipperman Heine	director	1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Teri Woodwick Sides	officer: Senior VP and CMO	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gregg S Sutton	officer: VP of Research and Development	6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Susan E Knight	director	9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437
Bryan K Phillips	officer: Dep. Gen. Counsel & Corp. Sec.	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344